NCT03601455View on ClinicalTrials.gov

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 26, 2018

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Bladder Urothelial CarcinomaStage IV Bladder Cancer AJCC v8Stage IVA Bladder Cancer AJCC v8Stage IVB Bladder Cancer AJCC v8
Interventions
BIOLOGICAL

Durvalumab

Given IV

RADIATION

External Beam Radiation Therapy

Undergo EBRT

BIOLOGICAL

Tremelimumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER